Alkermes plc: Alkermes Presents New Data From Psychiatry Por

- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented

Related Keywords

New York , United States , Massachusetts , Italy , Athlone , Westmeath , Ireland , Ohio , Waltham , Dublin , Alex Braun , Craig Hopkinson , Marisa Borgasano , Aripiprazole Lauroxil , Behavioral Health System , Research Databases , Alkermes , Schizophrenia International Research Society , Ibm , Research Development At Alkermes , Department Of Psychiatry , Nasdaq , Icahn School Of Medicine At Mount Sinai , Alkermes Inc , Alkermes Pharma Ireland , Results Presented From , Early Phase , Patients Early , New York Assessment , Adverse Cognitive Effects , Neuropsychiatric Treatment , Chief Medical Officer , Executive Vice President , Young Adults , Schizophreniform Disorder , Bipolari Disorder Who Are Early , Their Illness , Joseph Klingenstein Professor , Icahn School , Pharmaceutical Pipeline , Poster Session , Structured Benefit Risk Assessment , Prescription Dispensing Patterns , Real World Evidence , Comorbidities Associated With Olanzapine , Real World Data , Patients With Schizophrenia , Versus Caregiver , Clinician Reports , Cognitive Difficulties , Schizophrenia Switching , Post Hoc , Prescribing Information , Adverse Reactions , Elderly Patients , Dementia Related Psychosis , Boxed Warning , Severe Opioid Withdrawal , Physiologically Dependent , Life Threatening Opioid Overdose , Malignant Syndrome , Systemic Symptoms , Motor Impairment , Temperature Dysregulation , Combination Treatment , Mixed Episodes , Including Stroke , Medication Errors , Diabetes Mellitus , Temperature Regulation , Observed Adverse Reactions , Site Reactions , Alkermes Pharma Ireland Limited , Presents , Data , Rom , Sychiatry , Portfolio , 022 , Congress , Schizophrenia , Nternational , Research , Society ,